F-Star GmbH of Vienna will discover engineered antibodies for three inflammatory targets supplied by Merck Serono SA of Geneva in a contract that is potentially worth €492 million plus tiered royalties on product sales. ---Subscribe to MedNous to access this article--- Company News Regenerative Medicine
